It’s is the end of Alzheimer’s Awareness Month, but our hope for a cure for this disease will not end.
They may not remember us, but we need to remember that Alzheimer’s battle is not theirs alone, but all of ours.
DelveInsight Blog
Trending:
FDA rejects BioMarin’s Valoctocogene...
Aug 20, 2020
FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemop...
Gilead’s remdesivir trials; F2G rais...
Aug 13, 2020
Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID...
Roche-UCB’s $120M collaboration; Ome...
Jul 30, 2020
Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 mi...
Sign Up and Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Editor's Pick
Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epid...
Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history ...
Can FcRn Antagonists Be The Game-Changer in the Generalized Myasthenia Gravis...
Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 ...
Exploring Potential New Avenues for Bronchopulmonary Dysplasia Treatment
Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of low-we...
A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment
Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landsc...
NexoBrid and its Awaiting US Approval
A Burn takes place when the skin comes into contact with a heat source. Burns can occur...
RECENT ARTICLES
-Agonist.png "Toll-like Receptors Agonist")
